

Articles + Publications | February 6, 2024

Troutman Pepper Cannabis Communications Newsletter — February 6, 2024

WRITTEN BY

[Cole White](#) | [Jean E. Smith-Gonnell](#) | [Agustin E. Rodriguez](#)

Troutman Pepper's Cannabis Practice helps clients throughout their business cycle enter or expand into the cannabis space. Our team combines the resources of attorneys in areas such as licensing and taxation, regulatory compliance, corporate and transactional, intellectual property, and real estate, among others, to provide comprehensive services.

Our Cannabis Practice provides advice on issues related to applicable federal and state law. Marijuana remains an illegal controlled substance under federal law.

CANNABIS REGULATORY UPDATES

FROM “HIGH POTENTIAL FOR ABUSE” TO “ACCEPTED MEDICAL USE”: TRACKING DEVELOPMENTS AND POSSIBLE OUTCOMES OF FEDERAL CANNABIS RESCHEDULING IN THE U.S.

By [Jean Smith-Gonnell](#) and [Cole White](#)

Whether you believe that cannabis legalization has occurred too quickly or too slowly, one thing is certain: recent developments herald a potentially seismic shift in federal cannabis policy in the U.S. Reflecting on our article from September, which discussed the [U.S. Department of Health and Human Services' \(HHS\) recommendation to the Drug Enforcement Administration \(DEA\) to reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act \(CSA\)](#), it is clear that the landscape continues to evolve rapidly. Since that publication, numerous noteworthy developments have unfolded, along with a growing discourse on the potential unintended consequences of such a reclassification. This article aims to catch readers up on the latest developments in federal cannabis legalization.

[Read More](#)

RELATED INDUSTRIES + PRACTICES

- [Cannabis](#)
- [Regulatory Investigations, Strategy + Enforcement](#)